The DOI matches its Crossref record; 377 of the 378 references it cites were found in a registry or an index.
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Open accessAbstract
Novel targets to arrest neurodegeneration in several dementing conditions involving misfolded protein accumulations may be found in the diverse signaling pathways of the Mammalian/mechanistic target of rapamycin (mTOR). As a nutrient sensor, mTOR has important homeostatic functions to regulate energy metabolism and support neuronal growth and plasticity. However, in Alzheimer’s disease (AD), mTOR alternately plays important pathogenic roles by inhibiting both insulin signaling and autophagic removal of β-amyloid (Aβ) and phospho-tau (ptau) aggregates. It also plays a role in the cerebrovascular dysfunction of AD. mTOR is a serine/threonine kinase residing at the core in either of two multiprotein complexes termed mTORC1 and mTORC2. Recent data suggest that their balanced actions also have implications for Parkinson's disease (PD) and Huntington's disease (HD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). Beyond rapamycin; an mTOR inhibitor, there are rapalogs having greater tolerability and micro delivery modes, that hold promise in arresting these age dependent conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 mTORC1 pathway and regulatory protein changes in human brain. Relative levels of phosphorylated forms and activity status of several major mTOR pathway components and regulators (PTEN, mTORC2, REDD1, AMPK) in neurodegenerative disorders. Only those studies that examined human AD/DS (Alzheimer's, Down's Syndrome), PD (Parkinson's), HD (Huntington's) or ALS (Amyotrophic Lateral Sclerosis) brain or peripheral cells (WBCs) are listed. In addition to those studies cited in Table 1, that examined mTOR pathway proper, we include those here that did not but still focus on one or more of the other components. In so far as the number of studies supporting a given direction of change (references reporting decreased levels in blue, increased in red, in affected vs. control brain) can be taken as some measure of consensus, each publication listed is represented visually by a single red (increased) or blue (decreased) dot next to the respective pathway protein. The dot also indicates the corresponding disease. Most studies only examined basal phospho-levels, whereas a few specified insulin-induced activations or assayed the enzymatic activity. For example, the majority of studies in AD brain favor basal mTORC1 over-activation (vs. inhibition; n=11 vs. 5); increased IRS-1 phospho-inhibition (5); AMPK over-activation (4) and increased 4EBP1 phospho-inhibition (5 vs. 2), whereas a more modest majority, favors Akt over-activation (8 vs. 5) and p-p70S6K hyperactivation (7 vs. 5). Nevertheless, the Akt and mTOR activation responses to insulin are depressed in cell model [135] and AD brain [136]](https://figures.cochat.ai/paper-figures/85004ddcf76248a3a1cc322553f61d0f/mammalian-mechanistic-target-of-rapamycin-mtor-complexes-in-neurodegeneration-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some drugs targeting mTORC1 have been demonstrated in animal studies to effectively inhibit abnormal mTORC1 activation, thereby enhancing autophagy, reducing Aβ and tau pathology, and helping to delay cognitive decline. However, some studies express divergent views on the activity of mTORC1 in AD.340”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [340]
In the citing paper
“while rapamycin has also been shown to be neuroprotective in ALS and FTD.420”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [420]
In the citing paper
“tau phosphorylation and Aβ metabolism likely hyperactivate mTOR in Alzheimer’s disease and Down syndrome, indicating that disruption of autophagy in Alzheimer’s disease-related neurodegenerations is mTOR-independent [90–92].”
In the citing paper
“mTOR inhibition has been shown to only minimally activate autophagy in primary hippocampal neurons”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedCaccamo, A., Belfiore, R., & Oddo, S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.032 · Cited by 31
RetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“poral/inferior parietal lobules regions of the brain, resulting in early memory dysfunction [114, 115].”
BackgroundmTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 1×
“By inhibiting mTORC1 via TSC2, one consequence of activated AMPK is to facilitate autophagy [37, 38].”
BackgroundPhosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“340 Furthermore, the increased production of in fl ammatory mediators like TNF-α and the activation of stress kinases such as JNK, PKR, and IKK could promote the inhibitory serine phosphorylation of IRS-1, down-regulate insulin signaling in the brain, and induce AD neurological dysfunction.”
BackgroundRedox regulation: mechanisms, biology and therapeutic targets in diseases
Li, B., Ming, H., Qin, S., Nice, E. C., Dong, J., Du, Z., & Huang, C. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02095-6 · Cited by 317
Targeting ageing with rapamycin and its derivatives in humans: a systematic review
Lee, D. J. W., Hodzic Kuerec, A., & Maier, A. B. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00258-1 · Cited by 175
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Huang, J., Chen, L., Wu, J., Ai, D., Zhang, J., Chen, T., & Wang, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01070 · Cited by 168
Metadata
- Authors
- Querfurth, H., & Lee, H.-K.
- Affiliations
- Tufts Medical Center (US)
- Corresponding author
- Querfurth, Henry
- ORCID
- Lee, Han-Kyu
- Venue
- Molecular Neurodegeneration
- Published
- 2021-07-02
- Volume
- 16
- Issue
- 1
- Pages
- 44-44
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC8252260
- OpenAlex
- W3174082797
- Cited by
- 288
- References
- 378
- Citations by year
- 2026: 41 · 2025: 76 · 2024: 73 · 2023: 54 · 2022: 38 · 2021: 6
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute on Aging (AGO44871-01)
- the Bennett Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- mTOR, mTORC1, mTORC2, neurodegeneration, Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal dementia, amyotrophic lateral sclerosis, autophagy, amyloid-beta, tau phosphorylation, insulin signaling, cerebrovascular dysfunction, rapamycin, rapalogs, nutrient sensing, energy metabolism, neuroplasticity
- MeSH terms
- Animals, Humans, Nerve Degeneration, Neurodegenerative Diseases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. https://app.cochat.ai/papers/10.1186/s13024-021-00428-5
- The paper
- Querfurth, H., & Lee, H.-K. (2021). Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-021-00428-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.